A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease

J. C. Mansfield, M. Parkes, A. B. Hawthorne, A. Forbes, C. S. J. Probert, R. C. Perowne, A. Cooper, J. B. Zeldis, D. C. Manning, C. J. Hawkey

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)


Therapy targeted at tumour necrosis factor-alpha has an established role in Crohn's disease. Lenalidomide, an analogue of thalidomide, is an oral immunomodulatory agent with powerful antitumour necrosis factor-alpha properties. It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn's disease.
Original languageEnglish
Pages (from-to)421-430
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Issue number3
Publication statusPublished - 1 Aug 2007


  • Adolescent
  • Adult
  • Aged
  • Crohn Disease
  • Double-Blind Method
  • Female
  • Humans
  • Immunosuppressive Agents
  • Male
  • Middle Aged
  • Placebos
  • Severity of Illness Index
  • Thalidomide
  • Treatment Outcome
  • Venous Thrombosis

Cite this